Saturday, January 21, 2006


Hepatitis C Virus Lives In Your Liver(NC)-Your liver (Chronic Hepatitis C)

Hepatitis C Virus Lives In Your Liver

(NC)-Your liver works 24 hours a day, performing over 500 vital functions for your body. Most of the blood that returns to your heart passes through the liver. Your body can't function without it.

The hepatitis C virus lives in your liver. It inflames liver cells, which, over time, affects the way your liver functions. The effect of the hepatitis C virus varies from person to person. There is no way to predict how your body will react to it. There are, however, some things that are known:

You can live with hepatitis C for many years without experiencing any major symptoms, or you might simply feel tired. Symptoms can come and go over time. Their presence or absence does not tell you the degree to which liver damage may or may not be occurring. p>

Chronic, long-term inflammation of the liver can cause liver cell damage and result in fibrosis (liver scarring), or even cirrhosis. This damage can occur in as little as five years, or as long as 30 years.

About 20% of chronic hepatitis patients develop cirrhosis within 10 to 20 years.

Use of recreational drugs or alcohol can speed up inflammation and the development of fibrosis or cirrhosis.

There is an increased risk of liver cancer in people with cirrhosis.

The good news is that current drug treatments can be very effective for people with hepatitis C. Combined with proper nutrition, plenty of rest, and avoidance of recreational drugs and alcohol, these treatments help many who have the virus lead relatively healthy lives.

If you think you may be at risk of getting hepatitis C, see your doctor. The virus can be detected by a simple blood test. For more information on how to keep your liver happy and healthy, visit Health Canada's Web site at www.healthcanada.ca/hepc.

About The Author

p>

News Canada provides a wide selection of current, ready-to-use copyright free news stories and ideas for Television, Print, Radio, and the Web.

News Canada is a niche service in public relations, offering access to print, radio, television, and now the Internet media, with ready-to-use, editorial "fill" items. Monitoring and analysis are two more of our primary services. The service supplies access to the national media for marketers in the private, the public, and the not-for-profit sectors. Your corporate and product news, consumer tips and information are packaged in a variety of ready-to-use formats and are made available to every Canadian media organization including weekly and daily newspapers, cable and commercial television stations, radio stations, as well as the Web sites Canadians visit most often. Visit News Canada and learn more about the NC services. p>



Hepatitis C (Chronic Hepatitis C)


Hepatitis C
The diagnosis of chronic hepatitis C is made by history, ... Most patients with chronic hepatitis C will be asymptomatic or have non-specific symptoms such ...

Hepatitis C Complete health information regarding HCV on ...
Once established, chronic hepatitis C virus infection causes an inflammation of the liver called chronic hepatitis. This condition can progress to scarring ...

Management of Chronic Hepatitis C: Summary of Evidence Report ...
Chronic hepatitis C is often asymptomatic but may lead to cirrhosis of the ... The 10-year survival of those with chronic hepatitis C is approximately 50 ...

HEPATITIS C INFO CENTER - With Daily Hepatitis C Updates
Romark to Develop Alinia(R) (nitazoxanide) as New Treatment for Chronic Hepatitis C National AIDS Treatment Advocacy Project Jan 16 2006 5:17AM GMT ...

Friday, January 20, 2006


A Summary of Chronic Hepatitis C InfectionHepatitis C (Chronic Hepatitis C)

A Summary of Chronic Hepatitis C Infection

Hepatitis C is a stealthy virus that mutates while hiding in liver cells and other organ cells like the spleen and gall bladder. The fact that the viral cells "hide" makes it very difficult for the body's immune system to eradicate it. Hepatitis C is a slowly progressing disease sometimes taking many years until symptoms are noticeable. It is at this point that the virus has reached advanced chronic stage and becomes difficult to eradicate. Hepatitis C results in 8,000 to 10,000 deaths annually. Hepatitis C is also the leading cause of liver transplants in the U.S.

Hepatitis C infection is caused by blood contact with someone who has the virus infection himself. The transmission of the virus can occur by illicit drug use with needles, sharing toothbrushes or razors with an infected person, by sexual means, by unsanitary tattooing or by exposure to blood at your workplace (like a hospital or blood bank). Some HCV infection may have been caused by receiving blood from a transfusion prior to 1992.

Hepatitis C is diagnosed via a blood test. Usually, the first thing that is noticed is that the liver enzyme levels for ALT and AST are elevated well above normal levels. Further investigation via HCV-RNA testing identifies whether the Hepatitis C virus is in your blood or not. Other tests for HCV include qualitative viral load tests, which measure the RNA particles in your blood. If you are being treated for HCV, your doctor is probably using either a HCV-RNA or viral load test to determine the effectiveness of the treatment.

The symptoms of Hepatitis C infection often do not occur in a person until 20 years after he/she had been infected. Since the HCV infects the liver and the liver is the organ in the body that makes all the energy for our daily activities possible, liver function deterioration often results in fatigue. Fatigue is the primary complaint or symptom of HCV infection. Other more severe symptoms are jaundice (yellowing of the skin/eyes), bile retention (which can cause jaundice), portal vein hypertension, skin rashes and itching, and autoimmune problems resulting from your body's immune system attacking normal cells.

Long term HCV infection may result in fibrosis or even cirrhosis of the liver. Fibrosis results from unchecked liver inflammation. As the HCV infection progresses, the damage to the liver results in scarring or hardening of the liver cells (fibrosis). Long term fibrosis may lead to cirrhosis which is when the scarring from fibrosis overtakes the normal liver cell structure causing deformity and loss of function in the liver. About 15%-20% of HCV patients end up with cirrhosis. A liver biopsy is currently the most accurate means of determining the amount of inflammation and fibrosis the liver has sustained.

Hepatitis C progression in the body can take several years or even decades to come to chronic stage or to a stage where severe liver damage is evident. This period of time allows a person to determine how to properly treat the disease and to decide on a course of disease management. Currently, the main treatment for HCV infection to eradicate the virus is combo alpha-interferon and Ribavirin. Sometimes a doctor may prescribe interferon alone. Interferon comes in standard form or in pegylated form. Standard form interferon is administered 3 times per week, while the pegylated form is administered only once per week. Your body makes its own interferon, which is a protein that fights viral infection and viral replication.

Hepatitis C may often be managed by taking herbal and vitamin supplements that help your body fight infection and limit inflammation. These supplements help your liver with the inflammation and give it the nutrients it needs to regenerate healthy new cells. Your doctor can recommend alternative or adjunct solutions you may want to try.

Proper treatment of the disease, a healthy and active lifestyle, a good diet, abstinence from alcohol and stress management are important factors in controlling Hepatitis C progression.

About the Author

Greg Lietz is a freelance writer and internet businessman. His main website is http://www.theonlinebizplace.com where he provides content about internet based business opportunities and different niche interests. This article may be freely printed when the bio information is included.

Thursday, January 19, 2006


Hepatitis C (Chronic Hepatitis C)


Hepatitis C
Title: Hepatitis CCategory: Diseases and ConditionsCreated: 12/31/1997Last Editorial Review: 9/17/2005

VX-950 To Get Fast Tracked
As you may recall we've been saying VX-950 is the revolutionary new therapy to watch for HCV. Now it looks like the FDA agrees this treatment is quite promising and deserving of faster approval than a lesser worthy approach. Another...

HCV Vaccine Progress
The development of a HCV vaccine is very exciting, even to patients already infected. Although the vaccine will not help them direcly, it shows definite progress in understanding and outsmarting this virus that is known to be difficult to combat...

Deutsches Hepatitis C Forum eV - International Homepage (Chronic Hepatitis C)


Deutsches Hepatitis C Forum eV - International Homepage
- [ Translate this page ]Deutsches Hepatitis C Forum eV - International Homepage is a source of information about the rising epidemic: Hepatitis C. What it is, treatments, ...

Hepatitis C
NEW: The Hepatitis C Sourcebook. By Howard J. Worman, MD. The Hepatitis C Virus (HCV). HCV was discovered in 1989 by investigators at Chiron, Inc. Portions ...

Hepatitis C: Fact Sheet | CDC Viral Hepatitis
There is no vaccine to prevent hepatitis C. Do not shoot drugs; ... Hepatitis C. HCV positive persons should be evaluated by their doctor for liver disease. ...

Hepatitis C
Copyright 1998 Trustees of Dartmouth College. An Important Message from Dr. Koop Contents · Search · Glossary · About the Site.

Wednesday, January 18, 2006


Treating Chronic Mutational Hepatitis B with Chinese Medicine (Chronic Hepatitis C)

Treating Chronic Mutational Hepatitis B with Chinese Medicine Vitalliver (Vigconic Suppositories)


Treating chronic mutational hepatitis B with Chinese medicine Vitalliver (Vigconic suppositories)


ZHANG GUAN HUA, LIANG CHAO, ZHENG WAN PIN


Chengdu University of TCM, Hepatitis Laboratory in the attached hospital of Chengdu University of TCM, Sichuan, China

Research Method:

Quantitative determination by contrasting HBV-DNA of cases before and after the treatment.

Number of cases: 25 (n)

Case Selection: Between the age of 16 and 65, in accordance with the diagnosis standards pf chronic Hepatitis B, with negative e antigen and positive e antibody, HBV-DNA > 1 104 cp/mL.

Detection Method: All the blood samples are detected by Sichuan Clinical Detection Center; PCR-ELISA quantitative determination is used within detection range of 1 104 - 1 107-8, HBV-DNA, unit of measurement is cp/mL.

Direction Plan: one suppository provided by Vigconic (International) Ltd. Bid. The course of treatment is six months, the tracing observation after withdrawal lasts six months.

Observation index:


  1. HBV-DNA response after the treatment.

  2. Lasting HBV-DNA response (six months after withdrawal).
    p>

Criterion of Therapeutic Effect:


  1. If HBV-DNA volume 1 104 cp/mL: 4/25 (16%)

  2. Lasting response:


HBV-DNA volume 1 104 cp/mL: 2/25 (8%)

Among the results of lasting response, 16 blood serum samples are detected through fluorimetric quantitative determination PCR by the instruments of PE.USD, H-7700 in the second attached hospital of Guangzhou Medical College. The result is in accordance with that in Sichuan Clinical Testing Center. (8 cases among it 1 102 cp/mL). The testing range of this testing method is 1 102 - 1 107-8 cp/mL.

Conclusion

The reason for the repeatedly abnormal liver function of Chronic Hepatitis B (CHB) patients lies in the repeatedly duplication of HBV after infection, which leads to fibrosis of liver, then cirrhosis and liver cancer. It is commonly accepted that if CHB shows the transformation of HBeAg/Anti-HBe, HBV-DNA becoming negative, liver function returning to normal state, the disease is relieved. However, parts of patients with the transformation of HBeAg/Anti-HBe still remain positive in HBV-DNA and the pathological change in the liver continues. Because HBV-DNA occurs promoter mutation in the anterior C section (1896 necleoside G-A variation) or in the C section (1762 nucleoside T variation, 1764 G-A variation), HBeAg cannot come into being. Therefore, the HBeAg in the patient s blood cannot be detected, while the virus can keep on duplicating and fixing itself. Through sequential assay of nucleic acid, it proves that promoter mutation appears in 30%-60% of HBeAg negative Chronic Hepatitis B (CHB) in the anterior C section or in the C section. In some provinces and cities of the People of China, the percentage of promoter mutation appears in HBeAg negative Chronic Hepatitis B (CHB) in the anterior C section or in the C section is from 17.6% to 78.9%. Eight out of the 25 cases of our observation go through the sequential assay of nucleic acid carried out by the Department of Microbiology of the University of Hong Kong. It all proves to have HBV-DNA mutation. The chronic mutational Hepatitis B is infectious and apt to cause cirrhosis and liver cancer since the present medicines of antivirus and immuno-modulator do not produce the expected therapeutic effects.

Vitalliver suppository is made up from a formula of Chinese herbs, including Ginseng, Deer Horn, Cordyceps, Radix Astragali, Frudctus Cnidii, Semen Cuscutae, etc. The formula is mainly for strengthening the body resistant and primarily for reinforcing Kidney Qi, which produces good therapeutic effects in treating chronic mutational Hepatitis B. The mechanism is probably that through the regulating of immune system, the duplication of virus is inhibited and meanwhile the liver is protected, so it can produce a lasting therapeutic effect. No adverse reaction and severe accident happens during clinical observation, so it is safe for using. Vitalliver is bringing hopes to the treatment of chronic mutational Hepatitis B.

* The second stage of clinical trial would be carrying out by the Microbiology Department of the University of Hong Kong and Chengdu University of Traditional Chinese Medicine.

For more information, please visit: http://www.vigconic.com


Or, contact:


William Yip cs@vigconic.com
p>
5/F, Cheung Wah Building, Sheung Heung Rd,


Kowloon, Hong Kong


Tel: 852-27656200


Fax: 852-27645314
p>

Chengdu University of TCM, Hepatitis Laboratory in the attached hospital of Chengdu University of TCM, Sichuan, China


webmaster@vigconic.com

Tuesday, January 17, 2006


Prospect man waits for life Day-to-day (Chronic Hepatitis C)


Prospect man waits for life Day-to-day
Waterbury Republican-American - Copyright 2006 Republican-American PROSPECT -- For Donald Pranulis, sleeping through the night is a major accomplishment. So is maneuvering his way around his home, going out with his wife, or just having dinner with friends. Pranulis, who will

Difficulty In Treating Older Hepatitis C Patients With Combination
Medical News Today - A new study in Japan examining the effects of combination therapy on older patients with hepatitis C found more adverse effects necessitating discontinuation of treatment, lowering of dosages, and lower long-term benefits in this age group. The

HGS plans two late-stage trials in '06
Washington Business Journal - Tom Watkins, president and CEO of the Rockville-based biotechnology company, says HGS and its partner, British pharmaceutical giant GlaxoSmithKline , plan to begin Phase III development by year's end of their drug for treating patients with lupus

Monday, January 16, 2006


Living Well with Hepatitis C Virus Infection - BC HealthFile #40b (Chronic Hepatitis C)


Living Well with Hepatitis C Virus Infection - BC HealthFile #40b
Symptoms of acute hepatitis C infection may include: fever, tiredness, jaundice [yellow skin or eyes], abdominal pain, dark urine, loss of appetite, ...

Hepatitis C
What is the infectious agent that causes hepatitis C infection? Hepatitis C infection is caused by the hepatitis C virus. Hepatitis C virus is present in ...

Tattooing Is a Major Route of Hepatitis C Infection, Says Researcher
HIVandHepatitis.com: The Internet publication with accurate, timely and cutting-edge information on treatment and experimental vaccines for Hepatitis C.

Hepatitis C in Pregnancy
Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med. ...

Hepatitis C news, articles and studies, hep c information (Chronic Hepatitis C)


Hepatitis C news, articles and studies, hep c information
Chronic Hepatitis C in the Elderly The Effect of Ribavirin on Bone Density in Children with Chronic Hepatitis C Treated with Interferon-Ribavirin Liver Cirrhosis- and Hepatitis C

Hepatitis C Research 2005
Most chronic hepatitis C sufferers will develop cirrhosis in later life August 2005 Large European study finds HIV/HCV coinfected patients do not have an increased risk of HIV disease progression August

Hepatitis C and Complementary and Alternative Medicine: 2003 Update
National Institute of Diabetes and Digestive and Kidney Diseases. Chronic Hepatitis C: Disease Management . National Institute of Diabetes and Digestive and Kidney Diseases Web site. Accessed at

Sunday, January 15, 2006


Know the ABCs of hepatitis (Chronic Hepatitis C)


Know the ABCs of hepatitis
Packet Online, NJ - Dec 17, 2005... The most serious form of hepatitis hepatitis C (HCV) is considered an epidemic in this country. ... HCV is responsible for 8,000 to 10,000 deaths per year. ...

ICAAC: HCV only factor associated with liver problems in patients ...
Aidsmap, UK - Jan 8, 2006... 1485, 2005. Aranzabal L et al. Risk of HAART-associated hepatotoxicity in HIV/HCV coinfected patients with cirrhosis. 45 th Interscience ...

MedMira Granted Hepatitis C Patent in Europe
PR Newswire (press release), NY - Jan 3, 2006... NASDAQ: MMIRF) the global market leader in premium rapid diagnostic solutions, announced today that it has been granted a patent for the HCV Mosaic Antigen by ...

ING "Encouraged" By Innogenetics 06 Outlook
New Ratings - Dec 16, 2005... 2006. Analyst Richard Parkes warns guidance depends on court case over HCV genotyping and launch of new product lines. "Execution ...

Medivir: Candidate Drug Designated within the Tibotec ...
PharmaLive.com (press release), PA - Dec 29, 2005STOCKHOLM, Sweden--(BUSINESS WIRE)--Dec 29, 2005 - The Hepatitis C Virus (HCV) collaboration with Tibotec Pharmaceuticals Ltd has recently designated a ...